Tags:CenterDevelopmentDrugLifeScienceUniversity
Abarceo is a preclinical stage company, a spinout of Lund University Diabetes Center. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.
Member count: 11-50
Founded date: 2017

Investors 1

DateNameWebsite
02.03.2021Almi Inves...almi.se

Mentions in press and media 1

DateTitleDescriptionCategoryAuthorSource
13.06.202042 start-u...The EIT Health Catapult, curre...--eithealth....